-
Product Insights
Epilepsy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2025" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Alzheimer’s Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM. The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and...
-
Sector Analysis
Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
The Alzheimer’s Disease therapeutics market is entering a period of significant expansion, supported by advances in disease-modifying treatments and the growing approval of anti-Aβ monoclonal antibodies. As treatment innovation accelerates and diagnosis improves, the market is poised for substantial long-term growth across major global healthcare systems. GlobalData estimates that the Alzheimer’s Disease (AD) market across the eight major markets (8MM)—the US, France, Germany, Italy, Spain, the UK, Japan, and China—was valued at $2.4 billion in 2023. The market encompasses sales...
-
Sector Analysis
Parkinson's Disease in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. Across the 68 markets, sales in the Parkinson's Disease market were $5.1 billion in 2023, growing to $10.1 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 66.0% and 69.6% of 68-market sales in 2023 and 2033, respectively.
-
Sector Analysis
Parkinson's Disease Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimated that the PD market was $3.4 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.0 billion, increasing at a compound annual growth rate (CAGR) of 7.6%. The major drivers of growth in the PD market will be the launch of several pipeline products including novel...
-
Product Insights
Dementia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Dementia- Global Clinical Trials Review, 2025" provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials...
-
Product Insights
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome- Global Clinical Trials Review, 2025" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Spinal Muscular Atrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Spinal Muscular Atrophy (SMA) market through 2033. The diagnosed prevalent cases of SMA across the seven major markets are expected to increase from 18,621 cases in 2023 to 19,202 cases by 2033. The SMA market across the 7MM was valued at $2.7 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at...
-
Product Insights
Multiple Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Multiple Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Multiple Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034. GlobalData estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. The major drivers of growth in the PD market will be the launch of new disease modifying therapies...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.